Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1431-1439

  Von Hentig, Nils ^a,d   Müller, Axel ^b   Rottmann, Carsten ^b   Wolf, Timo ^b   Lutz, Thomas ^a   Klauke, Stephan ^a   Kurowski, Michael ^c   Oertel, Bruno ^a   Dauer, Brenda ^b   Harder, Sebastian ^a   Staszewski, Schlomo ^b  

^a Pharmazentrum Frankfurt ^*  (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ECZEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTOPENIA; MALE; MENTAL DISEASE; ORAL GLUCOSE TOLERANCE TEST; PANCREATITIS; POLYNEUROPATHY; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STOMACH ULCER; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ADULT; AGED; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SAFETY; SAQUINAVIR;

EID: 34247175708     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00854-06     Document Type: Article

References (52)

1. Barrios, A., A. Rendon, O. Rios, L. Martin-Carbonero, D. Gonzalez de Requena, O. Gallego, L. Valer, I. Maida, I. Jimenez-Nacher, J. Gonzalez-Lahoz, and V. Soriano. 2004. Atazanavir plasma levels associated with efficacy and safety in protease inhibitor-experienced HIV-infected patients, abstr. 606. Eleventh Conf. Retrovir. Oppor. Infect., San Francisco, CA.
2. Bittner, B., M. Riek, B. Holmes, and S. Grange. 2005. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir. Ther. 10:803-810.
3. Boffito, M., M. Kurowski, G. Kruse, A. Hill, A. A. Benzie, M. Nelson, G. Moyle, B. Gazzard, and A. Pozniak. 2004. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir boosted once-daily regimen. AIDS 18:1291-1297.
4. Boffito, M., D. Maitland, and A. Pozniak. 2006. Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies. J. Clin. Pharmacol. 46:130-139.
5. Boffito, M., D. Maitland, Y. Samarasinghe, and A. Pozniak. 2005. The pharmacokinetics of HIV protease inhibitor combinations. Curr. Opin. Infect. Dis. 18:1-7.
6. Cahn, P., N. Percival, P. Phanuphak, I. Sanne, T. Kelleher, and M. Giordano. 2001. Phase II 24-week data from study AI424-008: comparative results of BMS-232632, stavudine, lamivudine as HAART for treatment of naive HIV-infected patients, abstr. 5. First Int. AIDS Soc. Conf. HIV Pathog. Treat., Buenos Aires, Argentina.
7. Chiou, W. L., S. M. Chung, T. C. Wu, and C. Ma. 2001. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39:93-101.
8. Colonno, R., R. Rose, C. Ciani, G. Aldovani, N. Parkin, and J. Frigborn. 2003. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with the 150L substitution in HIV-protease, abstr. 597. Tenth Conf. Retrovir. Oppor. Infect., Boston, MA.
9. Cooper, C. L., R. P. van Heeswijk, K. Gallicane, and D. W. Cameron. 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 36:1585-1592.
10. Eagling, V. A., D. J. Back, and M. G. Barry. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:190-194.
11. Eagling, V. A., H. Wiltshire, I. W. Whitcombe, and D. J. Back. 2002. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17.
12. Food and Drug Administration. 2002. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: general considerations. www.fda.gov/cder/guidance/4964dft.pdf.
13. Gallant, J. E. 2000. Strategies for long-term success in the treatment of HIV infection. JAMA 283:1329-1334.
14. Gong, Y.-F., B. S. Robinson, R. E. Rose, C. Deminie, T. P. Spicer, D. Stock, R. J. Colonno, and P. F. Lin. 2000. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44:2319-2326.
15. Granfors, M. T., J. S. Wang, L. I. Kajosaari, J. Laitila, P. J. Neuvonen, and J. T. Backman. 2006. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. 98:79-85.
16. Heinzel, G. 1993. TOPFIT 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer Verlag, Stuttgart, Germany.
17. Hsu, A., G. R. Granneman, and R. J. Bertz. 1998. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 35:275-291.
18. Hsu, A., G. R. Granneman, G. Witt, C. Locke, J. Denissen, A. Molla, J. Valdes, J. Smith, K. Erdman, N. Lyons, P. Niu, J.-P. Decourt, J.-B. Fourtillan, J. Girault, and J. M. Leonard. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
19. Huisman, M. T., J. W. Smit, K. M. Crommentuyn, N. Zelcer, H. R. Wiltshire, J. H. Beijnen, and A. H. Schinkel. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301.
20. Huisman, M. T., J. W. Smit, H. R. Wiltshire, J. H. Beijnen, and A. H. Schinkel. 2003. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J. Pharmacol. Exp. Ther. 304:596-602.
21. Huisman, M. T., J. W. Smit, H. R. Wiltshire, R. M. Hoetelmans, J. H. Beijnen, and A. H. Schinkel. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:806-813.
22. Johnson, V., F. Brun-Vezinet, B. Clotet, B. Conway, D. Kuritzkes, D. Pillay, J. Schapiro, A. Telenti, and D. Richman. 2005. Update of the drug resistance mutations in HIV-1: fall 2005. Top. HIV Med. 13:125-131.
23. Kashuba, A., C. Tierney, G. Downey, E. Acosta, E. Vergis, and K. Klingman. 2005. Combining tosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A 5143 results. AIDS 19:145-152.
24. Kaul, S., K. Bassi, B. Damle, et al. 2003. Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenotovir disoproxil tumarate (TDF) for a once-daily antiretroviral regimen, abstr. A-1616. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
25. Kilby, J. M., A. Hill, and N. Buss. 2002. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med. 3:97-104.
26. Kilby, J. M., G. Sfakianos, N. Gizzi, P. Siemon-Hryczyk, E. Ehrensing, C. Oo, N. Buss, and M. S. Saag. 2000. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidosc ritonavir in human immunodeficiency virus-negative adults. Antimicrob. Agents Chemother. 44:2672-2678.
27. Kitchen, V. S., C. Skinner, K. Ariyoshi, E. A. Lane, I. B. Duncan, J. Burckhardt, H. U. Burger, K. Bragman, A. J. Pinching, and J. N. Weber. 1995. Safety and activity of saquinavir in HIV infection. Lancet 345:952-955.
28. Kurowski, M., T. Sternfeld, A. Sawyer, A. Hill, and C. Mocklinghoff. 2003. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 4:94-100.
29. Le Tiec, C., A. Barrail, C. Goujard, and A. M. Taburet. 2005. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44:1035-1050.
30. Lucia, M. B., C. Golotta, S. Rutella, E. Rastrelli, A. Savarino, and R. Cauda. 2005. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J. Acquir. Immune Defic. Syndr. 39:635-637.
31. Maserati, R., P. Villani, L. Cocchi, and M. Regazzi. 1998. Co-trimoxazole administered for Pneumocystis carinii pneumonia prophylaxis does not interfere with saquinavir pharmacokinetics. AIDS 12:815-816.
32. Montaner, J. S., P. R. Harrigan, N. Jahnke, J. Raboud, E. Castillo, R. S. Hogg, B. Yip, M. Harris, V. Montessori, and M. V. O'Shaughnessy. 2001. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15:61-69.
33. Mouly, S. J., M. F. Paine, and P. B. Watkins. 2004. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J. Pharmacol. Exp. Ther. 308:941-948.
34. Nettles, R., T. Kieffer, T. Parsons, J. Johnson, T. Quinn, B. Jackson, J. Cofranesco, J. Gallant, K. Carson, R. Siliciano, and C. Flexner. 2005. Frequent sampling in virologically suppressed patients taking HIV protease inhibitors of non-nucleoside reverse transcriptase inhibitors defines intraindividual pharmacokinetic variability, abstr. 642. Twelfth Conf. Retrovir. Oppor. Infect., Boston, MA.
35. Nieto-Cisneros, L., C. Zala, W. Fessel, J. Gonzalez-Garcia, C. Cohen, and R. McGovern. 2003. Atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in patients with virologie failure to a protease inhibitor (PI): 24-week results from BMS AI424-043, abstr. 117. Second Int. AIDS Soc. Conf. HIV Pathog. Treat., Paris, France.
36. Owen, A., B. Chandler, P. G. Bray, S. A. Ward, C. A. Hart, D. J. Back, and S. H. Khoo. 2004. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J. Virol. 78:12022-12029.
37. Park, S., and P. J. Sinko. 2005. P-Glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312:1249-1256.
38. Perloff, E. S., S. X. Duan, P. R. Skolnik, D. J. Greenblatt, and L. L. von Moltke. 2005. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33:764-770.
39. Profit, L., V. A. Eagling, and D. J. Back. 1999. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627.
40. Rodriguez Novoa, S., P. Barreiro, A. Rendon, A. Barrios, A. Corral, I. Jimenez-Nacher, J. Gonzalez-Lahoz, and V. Soriano. 2006. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42:291-295.
41. Rotger, M., P. Taffe, G. Bleiber, H. F. Gunthard, H. Furrer, P. Vernazza, H. Drechsler, E. Bernasconi, M. Rickenbach, A. Telenti, et al. 2005. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192:1381-1386.
42. Seminari, E., M. Guffanti, P. Villani, N. Gianotti, M. Cusato, G. Fusetti, A. Galli, A. Castagna, M. Regazzi, and A. Lazzarin. 2005. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprcnavir in HIV-1-infectcd patients. Eur. J. Clin. Pharmacol. 61:545-549.
43. Shen, D. D., K. L. Kunze, and K. E. Thummel. 1997. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 27:99-127.
44. Sinko, P. J., J. R. Kunta, H. H. Usansky, and B. A. Perry. 2004. Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. J. Pharmacol. Exp. Ther. 310:359-366.
45. Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, B. Dauer, et al. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58:1024-1030.
46. Staszewski, S., B. Dauer, C. Stephan, M. Kurowski, M. Stürmer, and P. Gute. 2002. A new strategy: boosted double protease inhibitor (PI) regimen lopinavir/r plus saquinavir (LPVr/SQV) without reverse transcriptase inhibitors (RTI), abstr. H-176. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., San Diego, CA.
47. Stephan, C., N. von Hentig, I. Kourbeti, B. Dauer, M. Mosch, T. Lutz, S. Klauke, S. Harder, and S. Staszewski. 2004. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ ritonavir. AIDS 18:503-508.
48. von Hentig, N., A. Mueller, A. Haberl, T. Lutz, G. Knecht, M. Kurowski, S. Harder, and S. Staszewski. 2004. Pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor therapy regimen, abstr. WeOrB1235. Fifteenth World AIDS Conf., Bangkok, Thailand.
49. Washington, C. B., H. R. Wiltshire, M. Man, T. Moy, S. R. Harris, E. Worth, P. Weigl, Z. Liang, D. Hall, L. Marriott, and T. F. Blaschke. 2000. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab. Dispos. 28:1058-1062.
50. Williams, P. E. O., G. J. Muirhead, M. J. Madigan, A. M. Mitchell, and T. Shaw. 1992. Disposition and bioavailability of the HIV-protease inhibitor Ro 31-8959 after single doses in healthy volunteers. Br. J. Clin. Pharmacol. 34:155P-156P.
51. Woodahl, E. L., Z. Yang, T. Bui, D. D. Shen, and R. J. Ho. 2005. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19:1617-1625.
52. Zhang, D., T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys. 2005. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33:1729-1739.